H.R. 1864

119th Congress

In Committee

Risky Research Review Act

Sponsored byRepublican:Rep. Griffith, H. Morgan [R-VA-9]VA· Introduced 5 mars 2025
Open on Congress.gov

0

Cosponsors

4

Actions

0

Amendments

0

Committees

—

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Referred to the Committee on Science, Space, and Technology, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

5 mars 2025·1 year ago

Summary

Introduced in House · Updated 13 mai 2025

Risky Research Review Act

This bill establishes the Life Sciences Research Security Board to oversee the award of federal funding for high-risk life sciences research. High-risk life sciences research means the study of an organism, virus, or related product that could be misapplied to pose a significant threat to the public or could enhance the transmissibility or virulence of certain high-risk pathogens (e.g., Ebola).

Specifically, the bill establishes the board as an independent agency that must review proposed high-risk life sciences research, determine whether a federal agency may award funding for the research, and determine minimum required controls for funded research. Entities that are seeking federal funding must attest to whether their research is high-risk life sciences research. Agencies must certify the validity of these attestations and submit proposed high-risk life sciences research to the board. Agencies must also notify the board of intended awards for other life sciences research for potential review.

In making its determinations, the board must consider specified factors, including whether the benefits of the research outweigh the risks. The bill prohibits agencies from awarding federal funding for high-risk life sciences research without approval of the board or for life sciences research currently under board review. The board may also review awards that were made before the bill’s enactment.

Entities that fail to properly attest to the nature of their research may lose their eligibility for funding. Additionally, agency employees who fail to comply with the bill's requirements are subject to disciplinary action.

Timeline

4 actions

  1. Referred to the Committee on Science, Space, and Technology, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    5 mars 2025 · IntroReferral

  2. Referred to the Committee on Science, Space, and Technology, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    5 mars 2025 · IntroReferral

  3. Introduced in House

    5 mars 2025 · IntroReferral

  4. Introduced in House

    5 mars 2025 · IntroReferral

Sponsorship

0 cosponsors

Sponsor

Republican:Rep. Griffith, H. Morgan [R-VA-9]VA

Classification

Policy area

Health

Legislative subjects

Accounting and auditingAdvisory bodiesBiological and life sciencesCongressional oversightEmployee performanceFederal officialsGovernment employee pay, benefits, personnel managementGovernment ethics and transparency, public corruptionGovernment information and archivesGovernment studies and investigationsInfectious and parasitic diseasesPublic contracts and procurement
Pelosi Tracker
Follow on XRejoignez notre Discord
PolitiquesProjets de loiPortefeuillesTarifsÀ proposMentions légalesConditions d'utilisationPolitique de confidentialité
English
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.